Sabrina Arena
Sabrina Arena
IRCC-University of Torino Medical School Laboratory of Molecular Genetics S.P. 142, km 3.95 Candiolo
Email verificata su
Citata da
Citata da
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
F Di Nicolantonio, M Martini, F Molinari, A Sartore-Bianchi, S Arena, ...
Journal of clinical oncology 26 (35), 5705-5712, 2008
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ...
The Journal of clinical investigation 120 (8), 2858-2866, 2010
Adaptive mutability of colorectal cancers in response to targeted therapies
M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ...
Science 366 (6472), 1473-1480, 2019
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ...
Cancer discovery 10 (8), 1129-1139, 2020
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
S Arena, B Bellosillo, G Siravegna, A MartÝnez, I Canadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells
H Konishi, M Mohseni, A Tamaki, JP Garay, S Croessmann, S Karnan, ...
Proceedings of the National Academy of Sciences 108 (43), 17773-17778, 2011
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ...
Nature communications 7 (1), 13665, 2016
High-dose vitamin C enhances cancer immunotherapy
A Magrý, G Germano, A Lorenzato, S Lamba, R ChilÓ, M Montone, ...
Science translational medicine 12 (532), eaay8707, 2020
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET
C Basilico, S Pennacchietti, E Vigna, C Chiriaco, S Arena, A Bardelli, ...
Clinical Cancer Research 19 (9), 2381-2392, 2013
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ...
Cancer research 76 (15), 4504-4515, 2016
Genetic analysis of the kinome and phosphatome in cancer
S Arena, S Benvenuti, A Bardelli
Cellular and Molecular Life Sciences CMLS 62, 2092-2099, 2005
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
F Di Nicolantonio, S Arena, M Gallicchio, D Zecchin, M Martini, SE Flonta, ...
Proceedings of the National Academy of Sciences 105 (52), 20864-20869, 2008
PIK3CA cancer mutations display gender and tissue specificity patterns
S Benvenuti, M Frattini, S Arena, C Zanon, V Cappelletti, D Coradini, ...
Human mutation 29 (2), 284-288, 2008
Expression and functional regulation of myoglobin in epithelial cancers
SE Flonta, S Arena, A Pisacane, P Michieli, A Bardelli
The American journal of pathology 175 (1), 201-206, 2009
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ...
Science translational medicine 8 (324), 324ra14-324ra14, 2016
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin
S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ...
Clinical Cancer Research 26 (6), 1372-1384, 2020
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer
FJ Sßnchez-MartÝn, B Bellosillo, M Gelabert-Baldrich, A Dalmases, ...
Clinical Cancer Research 22 (13), 3260-3267, 2016
p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells
KE Bachman, BG Blair, K Brenner, A Bardelli, S Arena, S Zhou, J Hicks, ...
Cancer biology & therapy 3 (2), 221-225, 2004
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20